AI Article Synopsis
- - The incidence of pure red cell aplasia (PRCA) in chronic lymphocytic leukemia (CLL) is less than 1%, with treatment options mainly involving steroids and immunosuppressive therapies.
- - A case study presented indicates a successful treatment of CLL-associated PRCA using acalabrutinib, marking the first reported use of this drug for this specific condition, which led to a quick response after two previous unsuccessful treatments.
- - The effectiveness of acalabrutinib may be attributed to its ability to modulate the immune response and maintain disease control, highlighting its potential as a treatment for autoimmune complications arising from CLL.
Article Abstract
The incidence of pure red cell aplasia (PRCA) in chronic lymphocytic leukemia (CLL) is <1% and treatments include the use of steroids and therapeutic strategies including immunosuppressive therapies. Here we present a case of a CLL-associated PRCA successfully treated with acalabrutinib, a treatment never described before for this specific condition, obtaining a rapid response after failing two lines of therapy. Exploring the treatment rationale, both the immune modulation and the continuous control of the disease, could have played a role in the treatment efficacy. Covalent BTK inhibitors are an effective treatment option for autoimmune complications of CLL, including CLL-associated PRCA.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555748 | PMC |
| http://dx.doi.org/10.1177/20406207241282570 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!